Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Psoriasis and seborrheic dermatitis are often viewed as ...
Hot off its first approval this summer in psoriasis, Arcutis Biotherapeutics’ roflumilast foam 0.3%, approved in cream form under the brand name Zoryve, is out to prove it’s no one-trick pony in itch.
When a person presents with features of both psoriasis and seborrheic dermatitis (SD), a healthcare professional may diagnose sebopsoriasis. This is a chronic skin condition that has symptoms that ...
This article was reviewed by Knox Beasley, MD. Flakes on your scalp making you feel self-conscious? Let’s talk about seborrheic dermatitis vs dandruff. Whether your scalp feels like a snowglobe thanks ...
WESTLAKE VILLAGE, Calif. and ORLANDO, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing ...
Arcutis Biotherapeutics will present two significant posters at the 2025 American Academy of Dermatology annual meeting, showcasing data that reinforces the efficacy and safety of ZORYVE treatments in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback